ABVC BIOPHARMA, INC.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on April 15, 2025
| ABVC BioPharma, Inc. | |
| By: | /s/ Uttam Patil |
| Uttam Patil | |
| Chief Executive Officer (Principal Executive Officer) | |
| By: | /s/ Uttam Patil |
| Uttam Patil | |
| Interim Chief Financial Officer (Principal Financial Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Uttam Patil | Chief Executive Officer (Principal Executive Officer) | April 15, 2025 |
| Uttam Patil | ||
| /s/ Uttam Patil | Interim Chief Financial Officer (Principal Financial Officer) | April 15, 2025 |
| Uttam Patil | ||
| /s/ Eugene Jiang | Chairman of the Board of Directors | April 15, 2025 |
| Eugene Jiang | ||
| /s/ Yen-Hsin Chou | Director | April 15, 2025 |
| Yen-Hsin Chou | ||
| /s/ Hsin-Hui Miao | Director | April 15, 2025 |
| Hsin-Hui Miao | ||
| /s/ Tsang-Ming Jiang | Director | April 15, 2025 |
| Tsang-Ming Jiang | ||
| /s/ Shuling Jiang | Director | April 15, 2025 |
| Shuling Jiang | ||
| /s/ Norimi Sakamoto | Director | April 15, 2025 |
| Norimi Sakamoto | ||
| /s/ Tsung-Shann Jiang | Director | April 15, 2025 |
| Tsung-Shann Jiang | ||
| /s/ Chang-Jen Jiang | Director | April 15, 2025 |
| Chang-Jen Jiang | ||
| /s/ Yoshinobu Odaira | Director | April 15, 2025 |
| Yoshinobu Odaira | ||
| /s/ Che-Wei Hsu | Director | April 15, 2025 |
| Che-Wei Hsu | ||
| /s/ Yu-Min (Francis) Chung | Director | April 15, 2025 |
| Yu-Min (Francis) Chung | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.